Skip to content

Characteristics of endomyocardial biopsies and their clinical relevance in patients with immune checkpoint inhibitor-associated myocarditis: a prospective cohort study

Characteristics of endomyocardial biopsies and their clinical relevance in patients with immune checkpoint inhibitor-associated myocarditis: a prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086238
Enrollment
Unknown
Registered
2024-06-27
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune checkpoint inhibitor-associated myocarditis

Interventions

MACE/non-MACE group:None

Sponsors

Department of Cardiovascular Medicine, Shanghai 10th People's Hospital Affiliated to Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >18 years old; (2) Confirmed myocarditis, the patient must be clearly diagnosed as myocarditis by a clinician, which can be diagnosed by clinical manifestations, electrocardiogram, myocardial enzyme indicators, cardiac ultrasound, etc.; (3) Receiving immune checkpoint inhibitors (ICI) : Patients must be treated with ICI, either as a single drug or in combination with other drugs; (4) Be able to understand the purpose of the research, voluntarily participate in the research and sign the informed consent

Exclusion criteria

Exclusion criteria: (1) have other known heart diseases, such as coronary heart disease, cardiomyopathy, etc.; (2) have other known causes of heart disease, such as infectious myocarditis, drug-related myocarditis, etc.; (3) have received a heart transplant or instrumental assisted treatment; (4) Severe cardiac insufficiency, NYHA grade III-IV; (5) Pregnant or lactating women; (6) Suffering from serious systemic diseases, such as advanced cancer, renal failure, etc., affecting the survival prognosis; (7) There are contraindications to myocardial biopsy; (8) Have severe cognitive or communication difficulties, unable to cooperate with research requirements; (9) The subject has participated or is participating in a clinical trial of any other device or drug within the last 3 months; (10) The investigator considers that the subjects have other conditions that are not suitable for clinical trials

Design outcomes

Primary

MeasureTime frame
One year of all-cause death;

Secondary

MeasureTime frame
MACE;Myocardial biopsy;

Countries

China

Contacts

Public ContactWenliang Che

Department of Cardiovascular Medicine, Shanghai 10th People's Hospital Affiliated to Tongji University

chewenliang@tongji.edu.cn+86 189 1768 4081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026